Sight Sciences, Inc. (SGHT)
- Previous Close
3.7700 - Open
3.7400 - Bid 3.5200 x 200
- Ask 3.7300 x 200
- Day's Range
3.6600 - 3.7400 - 52 Week Range
2.4900 - 8.4500 - Volume
4,170 - Avg. Volume
198,846 - Market Cap (intraday)
184.457M - Beta (5Y Monthly) 2.73
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0100 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.66
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
www.sightsciences.comRecent News: SGHT
View MorePerformance Overview: SGHT
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGHT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGHT
View MoreValuation Measures
Market Cap
190.00M
Enterprise Value
106.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
2.00
Enterprise Value/Revenue
1.34
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.30%
Return on Assets (ttm)
-19.41%
Return on Equity (ttm)
-45.36%
Revenue (ttm)
79.54M
Net Income Avi to Common (ttm)
-50.35M
Diluted EPS (ttm)
-1.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
118.56M
Total Debt/Equity (mrq)
37.16%
Levered Free Cash Flow (ttm)
-10.15M